Found 917 with Last Name = 'maxwell' and Initial = 'bd' 
Affinity DataKi: 10nMAssay Description:Agonist activity at human GPR40 expressed in CHO-A12 cells assessed as increase in intracellular calcium flux measured for 100 secs by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataKi: 13nMAssay Description:Agonist activity at human GPR40 expressed in CHO-A12 cells assessed as increase in intracellular calcium flux measured for 100 secs by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataKi: 35nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 39nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 45nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 49nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 60nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 73nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 180nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 310nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 310nMAssay Description:Agonist activity at human GPR40 expressed in CHO-A12 cells assessed as increase in intracellular calcium flux measured for 100 secs by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataKi: 360nMAssay Description:Agonist activity at human GPR40 expressed in CHO-A12 cells assessed as increase in intracellular calcium flux measured for 100 secs by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataKi: 890nMAssay Description:Agonist activity at human GPR40 expressed in CHO-A12 cells assessed as increase in intracellular calcium flux measured for 100 secs by FLIPR assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.30E+3nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 1.30E+3nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 1.80E+3nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 4.40E+3nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 6.50E+3nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 9.00E+3nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: 2.30E+4nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: >2.50E+4nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataKi: >3.30E+4nMAssay Description:Binding affinity to human GPR40 expressed in HEK293 cell membranes after 1 hr by radioligand displacement based scintillation counting methodMore data for this Ligand-Target Pair
Affinity DataIC50: 0.940nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 0.960nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 3.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 4.70nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 5.70nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 7.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 24nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 24nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
